EMS Publishers is an online publishing company, promoting open access scholarly journal academic research articles in Medical, Bio-Pharma, Life Sciences and Engineering
seen from Netherlands
seen from Spain

seen from Russia

seen from Lithuania
seen from Philippines
seen from United States

seen from Germany
seen from United States
seen from Türkiye

seen from United States

seen from Israel
seen from Yemen
seen from United States
seen from Germany

seen from Netherlands

seen from Netherlands

seen from Australia

seen from Germany
seen from Germany
seen from Brazil
EMS Publishers is an online publishing company, promoting open access scholarly journal academic research articles in Medical, Bio-Pharma, Life Sciences and Engineering
The Need for Comprehensive Care Apart from Treatment at Best Cancer Hospitals in Thrissur
In addition to having an impact on the body, cancer impacts mental well-being and even the patient’s lifestyle and family situation. Comprehensive care for oncology patients in modern cancer hospitals involves not only treatment but also other aspects of patients’ life. As one of the Best cancer hospitals in Thrissur, the hospital provides treatment, nutrition advice, and other types of assistance. Contact us- https://www.amalaims.org/hospital/ OR Dial-0487-2304000
REVLIMID (Lenalidomide) Approved by the European Commission as Monotherapy for the Maintenance Treatment of Patients with Newly Diagnosed Multiple Myeloma Feb 24, 2017
Celgene Announces Positive Results from Phase III SUNBEAM Trial of Oral Ozanimod in Patients with Relapsing Multiple Sclerosis
Celgene Announces Positive Results from Phase III SUNBEAM Trial of Oral Ozanimod in Patients with Relapsing Multiple Sclerosis
Feb 17, 2017
Celgene Corporation has announced that its phase III SUNBEAM trial that evaluates the safety and efficacy of ozanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with relapsing multiple sclerosis (RMS), met the primary endpoint in reducing annualized relapse rate (ARR), compared to weekly interferon (IFN) β-1a (Avonex®).
Top-line data show that…
View On WordPress
FDA Accepts Two sBLAs for the KEYTRUDA (pembrolizumab) of Merck for Locally Advanced or Metastatic Urothelial Cancer February 3, 2017